SYDNEY & AUCKLAND, New Zealand
As advised in our 7 June announcement of the trial results, Dr Barry Snow is presenting 81 week+ data on the safely and clinical effects of NTCELL in patients with Parkinson’s disease at the 20th International Congress of Parkinson’s Disease and Movement Disorders in Berlin. The presentation, in the form of a poster entitled “Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease (PD): 81 to 130 weeks follow-up” takes place at 12 noon Berlin time today.
Dr Snow, Principal Investigator for the trial, said, “This data shows a striking and significant improvement in all measurements of Parkinson’s disease in the four patients. Everything we measured has improved.”
Dr Ken Taylor, CEO of LCT, said, “The results of this clinical trial are consistent with what LCT has found in pre-clinical studies. Moreover microarray analyses identified that several nerve growth factors and nerve protective agents are released from NTCELL and this may explain the improvement observed in all of the measurements of Parkinson’s disease.”
The poster is available to view here.
For further information: www.lctglobal.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160622006576/en/
CONTACT
At the Company:
Ken Taylor, +64 9 276 2690
Chief
Executive
Mobile: +64 21 796 000
ktaylor@lctglobal.com
or
Media
Contact:
Botica Butler Raudon Partners
Rachael Joel, +64 9
303 3862
Mobile: +64 21 403 504
rachaelj@botica.co.nz
